The paper describes the development of supramolecular targeting chimeras (SupTACs), a modular platform designed for targeted protein degradation with high spatial and temporal precision. By utilizing self-assembling nanoparticles, this technology enables the selective elimination of disease-related proteins within specific organs like the liver and lungs. The researchers demonstrated the platform's versatility across multiple species, including mice, dogs, and non-human primates, to treat conditions such as acute lung injury. Furthermore, the use of chemically caged variants allows for on-demand activation of the degradation process through bioorthogonal chemistry. This innovation addresses the limitations of traditional therapies by providing a programmable and scalable approach to modulating protein functions in vivo. Overall, SupTACs represent a significant advancement in precision medicine and the study of complex biological signaling networks.

References:

• Liu J, Ma T, Yao R, et al. Multimodal supramolecular targeting chimeras enable spatiotemporally resolved protein degradation in vivo[J]. Cell, 2026.